D
Deborah Grady
Researcher at University of California, San Francisco
Publications - 276
Citations - 44747
Deborah Grady is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Estrogen & Hormone therapy. The author has an hindex of 88, co-authored 269 publications receiving 43348 citations. Previous affiliations of Deborah Grady include Veterans Health Administration & San Francisco General Hospital.
Papers
More filters
Journal ArticleDOI
Less is more: how less health care can result in better health.
Deborah Grady,Rita F. Redberg +1 more
TL;DR: Across the United States, the rate of use of common medical services varies markedly, but measures of health are not better in areas where more services are provided— in fact, the opposite is true— some measures ofhealth are worse in Areas where people receive more health services.
Journal ArticleDOI
Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy.
TL;DR: During the 6–8 months after publication of Women's Health Initiative trial findings, most regular postmenopausal HT users tried to stop using HT, despite not being well informed about the Women's health Initiative findings.
Journal ArticleDOI
Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study.
Deborah Grady,Deborah Grady,Kristine Yaffe,Kristine Yaffe,Margaret Kristof,Feng Lin,Cynthia Richards,Elizabeth Barrett-Connor +7 more
TL;DR: Among older postmenopausal women with coronary disease, 4 years of treatment with post menopausal hormone therapy did not result in better cognitive function as measured on six standardized tests.
Journal ArticleDOI
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
Kristine Yaffe,Kathryn A. Krueger,Steven R. Cummings,Terri Blackwell,Victor W. Henderson,Somnath Sarkar,Kristine E. Ensrud,Deborah Grady +7 more
TL;DR: Raloxifene at a dose of 120 mg/day, but not 60 mg/days, resulted in reduced risk of cognitive impairment in postmenopausal women.
Journal ArticleDOI
Likelihood Ratios for Modern Screening Mammography: Risk of Breast Cancer Based on Age and Mammographic Interpretation
TL;DR: The LRs for screening mammography interpreted as "suspicious for malignancy" are high and are associated with a substantial increase in the risk of breast cancer irrespective of age, but these interpretations comprise only a small proportion of abnormal mammography.